prism 10 (GraphPad Software Inc)
GraphPad Software Inc is a verified supplier 
90
Structured Review
GraphPad Software Inc
prism 10
Prism 10, supplied by GraphPad Software Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/imagej+open+source+software/prism+10/pm38985669-281-24-31
Average 90 stars, based on 1 article reviews
Prism 10, supplied by GraphPad Software Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/imagej+open+source+software/prism+10/pm38985669-281-24-31
Average 90 stars, based on 1 article reviews
prism 10 - by Bioz Stars,
2026-10
90/100 stars
Images
Related Articles
other:Article Title: Early and long-term effects of prophylactic and post-excision human papillomavirus vaccination on recurrent high-grade cervical intraepithelial neoplasia relative to margin status: a retrospective cohort study in the Czech Republic Article Snippet: Statistical analyses and regressions were conducted using Article Title: Comparative Analysis of GnRH Pulse Generator Activity in Intact and Gonadectomized Male and Female Mice Article Snippet: All statistical analyses were performed in Article Title: Decellularized cartilage scaffolds derived from wharton's jelly facilitate cartilage regeneration and inhibit angiogenesis Article Snippet: Article Title: Immunogenicity and innate immunity to high-dose and repeated vaccination of modified mRNA versus unmodified mRNA Article Snippet: The results were considered statistically significant when p < 0.05; analysis was done in Article Title: Protocol for evaluating compound uptake and RNase L co-localization in live cells using fluorescence-based binding, competition assay, and confocal microscopy Article Snippet: Article Title: Immunogenicity and safety of SARS-CoV-2 recombinant protein vaccine (CHO cell) LYB001 as a heterologous booster following two- or three-dose inactivated COVID-19 vaccine in adults aged ≥18 years: interim results of a randomized, active-controlled, double-blinded, phase 3 trial. Article Snippet: All analyses were performed via SAS software version 9.4 or higher, and figures were drawn via Article Title: TIGAR DEFICIENCY ENHANCES CARDIAC RESILIENCE THROUGH EPIGENETIC PROGRAMMING OF PARKIN EXPRESSION Article Snippet: |